More articles about Business News

The university will use the technology to screen blood samples for certain clinically actionable mutations in non-small cell lung cancer patients.

Invivoscribe submitted the LeukoStrat CDx FLT3 Mutation Assay as a companion diagnostic for Daiichi Sankyo's acute myeloid leukemia drug quizartinib.

Roche will develop an immunohistochemistry-based companion diagnostic for Daiichi's investigational HER2-targeting antibody conjugate for breast cancer.

The companies will bring NIPD Genetics' Veracity and Veragene noninvasive prenatal tests to Medicover's markets, as well as developing new genetic tests.

The companies will evaluate the performance of Proteomics International's PromarkerD test for predicting decline in kidney function and drug response.

LGC said the acquisition will improve its position across the clinical quality control tools market and increase its proficiency testing offerings.

The test is designed to detect clinically relevant genomic alterations — including somatic mutations, microsatellite instability, and viral DNA from ctDNA — in blood.

The classification indicates a reasonable probability that the use of, or exposure to, a recalled product will cause serious adverse health consequences or death.

The agreement amends and restates an existing loan and security agreement between NanoString and SVB to increase the size of the revolving loan facility to $20 million.

The drop in CGI's third quarter revenues reflect declines across the company's biopharma, clinical, and discovery services units.

The company reported revenues of $21.7 million compared to $11.1 million in the year-ago quarter, overshooting analysts' expectations of $17.5 million.

The company submitted the test to Japanese regulators for approval as a companion diagnostic for Daiichi Sankyo's acute myeloid leukemia drug quizartinib.

Developers of POC STI platforms and assays said that the tests provide convenience, privacy, and quick results in an area of testing in need of these benefits.

In the firm's first-ever earnings call, new CEO Jack Kenny said the firm will invest more in R&D to revamp its aging portfolio.

The company has entered into an accelerated share repurchase program with the bank to buy back a portion of its common stock.

The firm will use its solid-state nanopore technology to develop a point-of-care molecular diagnostic device to detect tuberculosis in low-resource areas. 

The firm intends to use the proceeds for working capital, general corporate purposes and the potential repayment of indebtedness.

The firm will use the financing to commercialize a test that utilizes metabolomic and DNA biomarkers to characterize obesity and guide weight loss.

Qorvo Biotechnologies and Novel Biomarkers Catalyst Lab are developing prototype cartridge-based HCV cAg assays for confirmatory testing.

The company's first product will use electronic health records, predictive blood-based biomarkers, and other genomic information to guide kidney disease treatment.

Pages